Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06832878 · ClinicalTrials.gov registry record · Phase 4
Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty
A Phase 4 study, sponsored by Mayo Clinic.
- Not yet
- Registry status
- Phase 4
- Development phase
- 101
- Enrollment target
NCT06832878: Clinical Trial Phase 4 study, sponsored by Mayo Clinic.
NCT06832878 is a Phase 4 study that has not yet begun recruiting, run by Mayo Clinic. The registered enrollment target is 101 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06832878, a Phase 4 study, has not yet begun recruiting, sponsored by Mayo Clinic.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 101 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.
Primary Outcome
The VAS is a 11-item questionnaire assessing pain. Using a scale of 0 = no pain to 10 = worst pain. Total scores range from 0 - 110, lower scores indicating lower pain and higher scores indicating greater pain.
Interventions
- DRUG Oral Tranexamic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What is known before NCT06832878 opens enrollment
NCT06832878 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Oral Tranexamic Acid is the first listed.
NCT06832878 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06832878 about?
NCT06832878 is a clinical study titled "Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty". The purpose of this study is to evaluate the impact of an extended oral Tranexamic Acid regimen on patient reported outcome scores, time to independent ambulation, postoperative range of motion, swelling, change in hemoglobin levels, 90-day complications, readmission and reoperation.
What is the current status of trial NCT06832878?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 101 participants. The study started on 2026-06-01. Estimated completion is 2026-06.
What interventions are being tested in trial NCT06832878?
The interventions under investigation include: Oral Tranexamic Acid (DRUG).
Who is sponsoring clinical trial NCT06832878?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06832878's enrollment target sits among peer trials
101 766th of 2000 higher than 1,231 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI